Dr. Shawn Baker has been involved in the field of genomics for over 25 years and has a broad range of skills and experience – advisor, business consultant, R&D, product development, and market management. His main focus is on genomics technologies – next generation sequencing, DNA synthesis, DNA editing – and their impact on diagnostics and healthcare. He covers technologies, platforms, and companies across the globe, with an emphasis on the US and China. In addition to helping Illumina grow from a small, 15-person startup to the dominant genomics leader, he co-founded AllSeq, the first online sequencing marketplace.

• Endpoint (5/2025) DNA giant Illumina spawned an ecosystem of competitors and customers
• Endpoints (2/2025) Roche no longer wants to be where ‘DNA sequencing goes to die'
• Synbiobeta (11/2024) Tiny Nanopores Spark Big Strides for Synthetic Biology
• Endpoints (10/2024) Illumina's pitch for new machines: You, too, can sequence DNA
• Endpoints (8/2024) Illumina wins FDA approval for test to identify treatable cancers
• STAT (8/2024) Illumina lays out plan to boost growth by helping scientists interpret sequencing data
• San Diego Business Journal (7/2024) Fluent Bio Acquisition Highlights Illumina Growth Strategy
• Mendelspod (11/2023) State of Sequencing 2023: Shawn Baker and Keith Robison
• Endpoints (8/2023) PacBio, once slated to be acquired by Illumina, is taking on the DNA giant
• Endpoints (8/2023) His tiny prenatal testing company has big plans after exacting legal revenge on lab giants
• Endpoints (6/2023) As it searches for a new CEO, Illumina faces a high-stakes year of challenges
• STAT (4/2023) Vast sequencing project begins to unlock human genome’s secrets — by deciphering other mammals’ DNA
• GEN (2/2023) The State of Genomics & NGS
• STAT (2/2023) Chinese DNA giant’s U.S. affiliate looks to rival Illumina, touting $100 genome and high-power sequencers
• Endpoints (1/2023) As Illumina disappoints Wall Street, competitors make their case at JPM
• STAT (1/2023) Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome
• GEN (1/2023) The NGS Race Is On: Souped-Up Sequencers Vie for Frontrunner Status
• GEN (1/2023) Complete Genomics Arrives Stateside, the Company Announces at JPM
• Front Line Genomics (12/2022) Advances in Genomic Sequencing Webinar 2: Panel Discussion
• STAT (10/2022) Pacific Biosciences, known for niche DNA sequencing, looks to rival Illumina with new product launch
• Inside Precision Medicine (10/2022) Is Clinical Next-Generation Sequencing on the Cusp of a Revolution?
• STAT (9/2022) With rivals on its heels, Illumina launches a new line of high-end DNA sequencers
• STAT (7/2022) ​​Genomics is racing toward a $100 genome. Are we ready for it?
• Endpoints (7/2022) DNA sequencing giant Illumina battles antitrust regulators and growing competition
• STAT (5/2022) A ‘dark horse’ emerges in the DNA sequencing race, boasting a $100 genome
• GEN (4/2022) NGS Upstarts Expected to Take On the Champion
• STAT (3/2022) Illumina sues Guardant Health, saying former employees stole trade secrets to launch liquid biopsy firm
• GEN (3/2022) Old Dogs, New Tricks: Element Biosciences Launches the AVITI
• STAT (3/2022) Armed with heaps of cash and a veteran team, an upstart looks to disrupt DNA sequencing
• GEN Live (2/2022) NGS Heats Up: What's Next for the State of Sequencing
• STAT (1/2022) Illumina’s embrace of long-read technology signals a shift in the DNA-sequencing market
• STAT (1/2022) Researchers shatter the speed record for diagnosing rare genetic diseases with DNA sequencing
• San Diego Union-Tribune (8/2021) FTC trial kicks off, with fate of Illumina’s acquisition of Grail hanging in the balance
• Clinical OMICs (7/2021) The Long and the Short of It: PacBio Strikes $800M Deal to Acquire Omniome
• Genetic Engineering & Biotechnology News (7/2021) PacBio Adds Short Read Capabilities with up-to-$800M Omniome Acquisition
• PR Newswire (2/2021) L.A based tech company Sci Find announces upcoming launch of AI-Powered search engine and database for Life Sciences
• Festival of Genomics & Biodata (1/2021) Discussion: The Merits and Shortfalls of Different Technologies (Vimeo)
• Genetic Engineering News (9/2020) Nanopore Sequencing Looks to the Long Haul
• Genetic Engineering News (3/2020)  Genomic Medicine Identifies Reconcilable Differences 
• The Verge (2/2020) Layoffs at genetic testing companies reflect the changing market 
• San Diego Business Journal (10/2019)  Illumina’s $1.2 Billion Acquisition of Pacific Biosciences Tentatively Rejected
• Clinical Omics (9/2019) Going Deeper into Long Reads: Oxford Nanopore Licenses CRISPR-Cas9 IP from Caribou
• Reorg M&A (9/2019)  PACB/ILMN: FTC Unlikely to Delay Merger Decision to Account for CMA Inquiry
• Biocompare (8/2019)  Cutting the Cost of Sequencing
• Genetic Engineering News (8/2019) DNA Sequencing Accuracy Comes a Long Way
• San Diego Business Journal (6/2019) UK Agency Says Illumina-Pacific Biosciences Deal Raises Concerns
• San Diego Business Journal (5/2019)  Illumina Dominates DNA Sequencing, But Potential Competition is Afoot
• Genetic Engineering New (3/2019) Sequencing Platforms Make a Splash on Marco Island at AGBT Meeting
• MLex Market Insight (1/2019) Illumina-PacBio antitrust review to focus on technological promise, falling prices, substitutability
• CTFN M&A Reporting (1/2019) Customers Comment on PacBio/Illumina
• The Capital Forum (1/2019) Illumina/Pacific Biosciences: Existing, Future Competition Questions Create Gene Sequencing Tie-up Antitrust Risk
• Genetic Engineering News (1/2019) All Aboard the Genome Express
• Mendelspod (11/2018) Keith Robison and Shawn Baker on Illumina Buyout of PacBio
• San Diego Business Journal (9/2018) ICYMI: Ex-Illumina Leaders Form Own Cos. To Pursue Genomics Work
• Biocompare (5/2018) The Long and the Short of Sequencing
• Genetic Engineering News (2/2017) Next-Generation Sequencing Challenges